45 related articles for article (PubMed ID: 16376131)
1. D-galactose supplementation in individuals with PMM2-CDG: results of a multicenter, open label, prospective pilot clinical trial.
Witters P; Andersson H; Jaeken J; Tseng L; van Karnebeek CDM; Lefeber DJ; Cassiman D; Morava E
Orphanet J Rare Dis; 2021 Mar; 16(1):138. PubMed ID: 33743737
[TBL] [Abstract][Full Text] [Related]
2. β-Glucose-1,6-Bisphosphate Stabilizes Pathological Phophomannomutase2 Mutants In Vitro and Represents a Lead Compound to Develop Pharmacological Chaperones for the Most Common Disorder of Glycosylation, PMM2-CDG.
Monticelli M; Liguori L; Allocca M; Andreotti G; Cubellis MV
Int J Mol Sci; 2019 Aug; 20(17):. PubMed ID: 31454904
[TBL] [Abstract][Full Text] [Related]
3. Establishment of a human induced pluripotent stem cell line（SDQLCHi059-A）from a patient with congenital disorder of glycosylation carrying heterozygous mutation in MPI gene.
Wang B; Yang L; Gao M; Zhang H; Liu Y; Gai Z
Stem Cell Res; 2024 Jun; 77():103381. PubMed ID: 38493608
[TBL] [Abstract][Full Text] [Related]
4. Motor improvement in children with PMM2-CDG syndrome following a six-month rehabilitation treatment utilising whole-body vibration; a retrospective study.
Bossier C; Stark C; Martakis K; Duran I; Schoenau E
J Musculoskelet Neuronal Interact; 2024 Mar; 24(1):12-21. PubMed ID: 38427364
[TBL] [Abstract][Full Text] [Related]
5. Congenital disorder of glycosylation type Ia in a Chinese family: Function analysis of a novel
Zhong D; Huang X; Feng T; Zeng J; Gu S; Ning F; Yang Y; Zhu J; Wang Y; Chen R; Ma G
Mol Genet Metab Rep; 2024 Jun; 39():101067. PubMed ID: 38433930
[TBL] [Abstract][Full Text] [Related]
6. Mutations in PMM2, a phosphomannomutase gene on chromosome 16p13, in carbohydrate-deficient glycoprotein type I syndrome (Jaeken syndrome).
Matthijs G; Schollen E; Pardon E; Veiga-Da-Cunha M; Jaeken J; Cassiman JJ; Van Schaftingen E
Nat Genet; 1997 May; 16(1):88-92. PubMed ID: 9140401
[TBL] [Abstract][Full Text] [Related]
7. Non-functional alternative splicing caused by a Latino pathogenic variant in a case of PMM2-CDG.
González-Domínguez CA; Villarroel CE; Rodríguez-Morales M; Manrique-Hernández S; González-Jaimes A; Olvera-Rodriguez F; Beutelspacher K; Molina-Garay C; Carrillo-Sánchez K; Flores-Lagunes LL; Jiménez-Olivares M; Muñoz-Rivas A; Cruz-Muñoz ME; Mora-Montes HM; Salinas-Marín R; Alaez-Verson C; Martínez-Duncker I
Mol Genet Metab Rep; 2021 Sep; 28():100781. PubMed ID: 34277356
[TBL] [Abstract][Full Text] [Related]
8. Cystic kidney diseases associated with mutations in phosphomannomutase 2 promotor: a large spectrum of phenotypes.
Dorval G; Jeanpierre C; Morinière V; Tournant C; Bessières B; Attié-Bittach T; Amiel J; Spaggari E; Ville Y; Merieau E; Gubler MC; Saunier S; Heidet L
Pediatr Nephrol; 2021 Aug; 36(8):2361-2369. PubMed ID: 33580824
[TBL] [Abstract][Full Text] [Related]
9. CDG Therapies: From Bench to Bedside.
Brasil S; Pascoal C; Francisco R; Marques-da-Silva D; Andreotti G; Videira PA; Morava E; Jaeken J; Dos Reis Ferreira V
Int J Mol Sci; 2018 Apr; 19(5):. PubMed ID: 29702557
[TBL] [Abstract][Full Text] [Related]
10. Exon-skipping antisense oligonucleotides to correct missplicing in neurogenetic diseases.
Siva K; Covello G; Denti MA
Nucleic Acid Ther; 2014 Feb; 24(1):69-86. PubMed ID: 24506781
[TBL] [Abstract][Full Text] [Related]
11. Human genetic variation recognizes functional elements in noncoding sequence.
Lomelin D; Jorgenson E; Risch N
Genome Res; 2010 Mar; 20(3):311-9. PubMed ID: 20032171
[TBL] [Abstract][Full Text] [Related]
12. Human Splicing Finder: an online bioinformatics tool to predict splicing signals.
Desmet FO; Hamroun D; Lalande M; Collod-Béroud G; Claustres M; Béroud C
Nucleic Acids Res; 2009 May; 37(9):e67. PubMed ID: 19339519
[TBL] [Abstract][Full Text] [Related]
13. PMM2 intronic branch-site mutations in CDG-Ia.
Vuillaumier-Barrot S; Le Bizec C; De Lonlay P; Madinier-Chappat N; Barnier A; Dupré T; Durand G; Seta N
Mol Genet Metab; 2006 Apr; 87(4):337-40. PubMed ID: 16376131
[TBL] [Abstract][Full Text] [Related]
14. Characterization of two unusual truncating PMM2 mutations in two CDG-Ia patients.
Schollen E; Keldermans L; Foulquier F; Briones P; Chabas A; Sánchez-Valverde F; Adamowicz M; Pronicka E; Wevers R; Matthijs G
Mol Genet Metab; 2007 Apr; 90(4):408-13. PubMed ID: 17307006
[TBL] [Abstract][Full Text] [Related]
15. Characterization of the 415G>A (E139K) PMM2 mutation in carbohydrate-deficient glycoprotein syndrome type Ia disrupting a splicing enhancer resulting in exon 5 skipping.
Vuillaumier-Barrot S; Barnier A; Cuer M; Durand G; Grandchamp B; Seta N
Hum Mutat; 1999 Dec; 14(6):543-4. PubMed ID: 10571956
[TBL] [Abstract][Full Text] [Related]
16. Functional analysis of three splicing mutations identified in the PMM2 gene: toward a new therapy for congenital disorder of glycosylation type Ia.
Vega AI; Pérez-Cerdá C; Desviat LR; Matthijs G; Ugarte M; Pérez B
Hum Mutat; 2009 May; 30(5):795-803. PubMed ID: 19235233
[TBL] [Abstract][Full Text] [Related]
17. [Molecular diagnosis of congenital disorders of glycosylation].
Vuillaumier-Barrot S
Ann Biol Clin (Paris); 2005; 63(2):135-43. PubMed ID: 15771971
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
